<i>catena</i>-Poly[[[bis-(quinoxaline-2-carboxyl-ato-κ<sup>2</sup> <i>N</i> <sup>1</sup>,<i>O</i>)zinc(II)]-μ<sub>2</sub>-1,2-bis-(pyridin-4-yl)ethene-κ<sup>2</sup> <i>N</i>:<i>N</i>'] hemihydrate]. [PDF]
Shehadeh RI +4 more
europepmc +1 more source
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF); Scientific Opinion on Flavouring Group Evaluation 17, Revision 2 (FEG.17Rev2): Pyrazine derivatives from chemical group 24 [PDF]
Aeschbacher +96 more
core +1 more source
Exploring novel of 1,2,4-triazolo[4,3-a]quinoxaline sulfonamide regioisomers as anti-diabetic and anti-Alzheimer agents with in-silico molecular docking simulation. [PDF]
Abusaif MS +7 more
europepmc +1 more source
Electrochemical Hydrogenation of Aza-Arenes Using H<sub>2</sub>O as H Source. [PDF]
Dutta S, Narobe R, Waldvogel SR.
europepmc +1 more source
Light-mediated CO release from a tricarbonyl manganese(i) complex with a bidentate quinoxaline ligand. [PDF]
Khaled RM +5 more
europepmc +1 more source
Facile Chemodivergent Synthesis of Fused Indolo[2,3‑<i>b</i>]quinoxalines and Benzo[4,5]imidazo[1,2‑<i>c</i>]quinazolin-6(5<i>H</i>)‑ones: An Organocatalytic Trifluoromethanesulfonic Acid-Controlled Mechanistic Switch between Condensation and Ring Expansion of the Isatin Core. [PDF]
Sheeba L +4 more
europepmc +1 more source
Thiadiazolobenzotriazole-Based Donor-Acceptor Terpolymers That Can Be Processed from Green Solvents and Deliver 950 nm Emission in Light-Emitting Electrochemical Cells. [PDF]
Tang S +9 more
europepmc +1 more source
Novel <i>N</i>-Alkyl 3-(3-Benzyloxyquinoxalin-2-yl) Propanamides as Antiproliferative Agents: Design, Synthesis, In Vitro Testing, and In Silico Mechanistic Study. [PDF]
Abubshait SA.
europepmc +1 more source
Antimutagenic effects of a tea made from Actinidia arguta, sarunashi in Japanese, and its inhibitory effects on the formation of aberrant crypt foci induced by 1,2-dimethylhydrazine in mice. [PDF]
Saiki Y, Miyake N, Arimoto-Kobayashi S.
europepmc +1 more source
CVN-424: An Advanced GPR6 Inverse Agonist in Phase III Clinical Trials for Parkinson's Disease. [PDF]
Tian X, Ali S, Allen JA, Zhou J.
europepmc +1 more source

